Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | ERCC1 | P07992 | 8/20 | 0.54 |
| ▸ | ERCC4 | Q92889 | 8/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2587661 | 0.84 | BACE1 (0.54) | EGFRCYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL2573822 | 0.83 | MMP12 (0.55) | EGFRCYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL2452462 | 0.83 | CYP1A2 (0.53) | EGFRERCC1ERCC4CYP1A2CYP2D6 | |
| SCHEMBL2564315 | 0.80 | HDAC1 (0.59) | EGFRERCC1ERCC4HDAC1 | |
| SCHEMBL2568596 | 0.79 | LMNA (0.48) | EGFRCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1730117 | 0.78 | LMNA (0.68) | EGFRCYP1A2CYP2D6CYP2C9TSHR | |
| SCHEMBL31225239 | 0.77 | GAA (0.63) | TSHRALOX5ALDH1A1LMNA | |
| SCHEMBL14832184 | 0.76 | ALOX5 (0.59) | EGFRTSHRALOX5ALDH1A1 | |
| SCHEMBL14081432 | 0.76 | CHRNB2 (0.71) | ERCC1ERCC4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2567972 | 0.76 | HTT (0.47) | EGFRCYP1A2CYP2D6CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | EGFR 4864/4885ERCC1 2744/4885ERCC4 979/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | EGFR 4879/4885ERCC1 2990/4885ERCC4 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.